Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(3.89)
# 576
Out of 4,786 analysts
10
Total ratings
40%
Success rate
20%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $9.15 | +118.58% | 3 | Mar 18, 2025 | |
| VRNA Verona Pharma | Initiates: Buy | $68 | $63.49 | +7.10% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $4.30 | +179.07% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.95 | +633.91% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.91 | +266.49% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $9.04 | +220.80% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.55 | +545.16% | 1 | Dec 5, 2024 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $9.15
Upside: +118.58%
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $63.49
Upside: +7.10%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $4.30
Upside: +179.07%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.95
Upside: +633.91%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.91
Upside: +266.49%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $9.04
Upside: +220.80%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.55
Upside: +545.16%